The deck is stacked against the avg Andres...Just trying to beat the odds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not true...
There are no stupid questions. If you think one is, why respond?
We know, as you stated, the DcVaxL platform does not have that safety risk or toxicity. Do we know to what extent/degree Covid vaccines are cause heart problems and inflammation in some patients?
Hear! Hear!
Who/What is Northwood. Do you mean Neil Woodford?
Hear! Hear!
Interesting video about NWBO's lawsuit...
Market Makers, Market Manipulators synonymous with Market Malefactors (i.e. CRIMINALS).
Hear! Hear! The SEC, FNRA, DTCC should all be sued too for allowing this shit to happen!
Since pps is a derivative of MC, I kind of use them interchangeably. In retrospect, I shouldn't, as you pointed out.
Yes, timing/value has always been an issue. But now we have facts, data validated by multiple impartial parties/experts. We may be irritated as hell with the speed of MC/pps movement (or lack thereof), but anyone who knows about the data/peer-reviewed analysis know it NWBO WILL be valued appropriately and handsomely soon. Can't say when... but it WILL happen.
I am old and feeble, but I went back through my original post and don't see where I made a point as to when NWBO's pps will reflect the value of DCVax. The fact of DCVax-L's efficacy is out! It is a product that fights (and could cure even) a fatal disease, eventually all tumor-based cancers. It will be in high world-wide demand. The international manufacturing of the product is highly scalable via Flaskworks with Interational mfg. expansion capability via CRL.
One can only conclude that DCVax will be properly valued. I won't share what I REALLY think the PPS will be. It sounds crazy when I say it outload, lol.
Honestly, I think the question is irrelevant at this point. The indisputable data is out. No one knows when the pps will reflect the true value DCVax but, given the peer-reviewed analysis of the data, we know that at some point soon (a week, a month, 6 months, a year), NWBO's pps WILL surely reflect the true value of DCVax.
Let me try this again, GI&SI.
Where the pps is today is NOT where it is going to be. The market doesn't have to believe in LP/NWBO today. They will eventually believe in JAMA, NYSA, ASCO and SNO. IMHO, there are leaders in wall street and BP who see exactly what is going on a hell of lot clearer than we do, especially Merc (and BMY too) who had a taste of the "secret sauce".
Nothing is falling in place? Really?
1. Efficacy is now beyond nGBM but also includes rGBM... bigger market.
2. Manufacturing in the U.S., Europe and the U.K is ready.
3. International manufacturing scalability via CRL/Flaskworks ready/near ready.
4. Trial completed, peer-reviewed and expertly analyzed by one of the most prestigious medical journals, JAMA.
5. FDA released a Tissue Agnostic Drug Development guidance doc whereby NWBO could expand approval to all tumor-based cancers instead of just n/rGBM right out of the gate.
But nothing at all is falling in place... nothing at all? Lol, seriously?
Now let's deal with the so-called issues you laid out.
NWBO's 20-year fight: There is nothing shameful/negative here. Anytime a radically different and disruptive product comes on the scene, it takes time for people-- the FDA, oncologists, and developers to understand the nuances surrounding it. It took time for NWBO to understand how to optimally tweak the secret sauce, to understand pseudo-progression, method A vs method B and a host of other nuances to which we are not even privy. I am sure there are others that I don't even remember.
Also, it took time for the FDA to understand these issues and how this new treatment would mesh with current FDA approval processes. Remember LP's approval process recommendation to FDA? Is it possible that FDA's process changes and its agnostic drug development guidance are at least in part related to LP/NWBO's effort? Keep in mind too that LP accomplished this with constant short attacks and even a wall-street wolf in sheep clothing posing as a friend, attempting to fleece LP/NWBO (he's no longer in business, by the way).
"she’s out of arrows": LMAO! LP is no longer fighting. The fighting is pretty much over. She won already; Don't you see? There is indisputable evidence...!!!DATA!!!... validated by 4 medical associations/journals/conferences. And, by the way, LP didn't use arrows. She used a dagger, sort of speak, and fought the fight up close and personal. No weapon formed against her prospered.
"the stock has fallen 25%!": So what? Radically disruptive products are never adopted until AFTER disruption starts to occur. Look at Dell, Apple, Google, Amazon, Netflix, etc. The supposedly smartest people in the room never see it coming until AFTER it slaps them in the face... hard. NWBO is no exception.
So, some will laugh at NWBO longs' position. They'll talk about "no results for xx more years" or "the market doesn’t give a shit!". This is common. It happened to every company that seeks to disrupt an industry with a radically superior product. I actually welcome opposing points of view. However, I prefer them with supporting facts over emotional unsupported statements alone (hint, lol).
I performed my dd, placed my bets and grow more enthusiastic by the day as there is credible supporting evidence to validate my position.
By the way, for those who hate NWBO/management or feel investing in it is a lost cause, there are a host of other "proven" undervalued stocks that are 30 -70% of their highs. If one doesn't like NWBO, find a stock/company one does like and respect and go spread the word.
I actually think it could be more than $50, though it's speculation. I base it on the PD1 combo-patent and the fact the 68% of tumors treated with DCVax-L start producing pd1 antigens. The combo is likely to be a cure for a high % of patients. Then add this tissue agnostic development guidance, potentially elevating DCVax-L's treatment target to all tumor-based cancers: DCVAX-L becomes highly disruptive to the industry.
And we ain't even talking about DIRECT: DCVax-L is a cancer treatment with the brakes on. DCVax-Direct is a cancer treatment with the brakes off.
When I look at the totality of the DCVax platform, I wonder if BP has enough $$$ to buy it.
NWBO/DCVax-L's potential here is phenomenal.
Yep. It's easy to be patient given the tld. Only a matter of time.
JAMA (along with NYAS, LL @ SCO & ASCO):
I agree... and I can't wait!
No, I have not lived in Canada to see their decisions in actions. I didn't live in Germany to see the decisions made by the Third Reich either. By your logic, I can't draw any conclusions about it unless I lived it?
Talk about my speculation re NWBO's pps or where you lived but you can't refute my point: If DCVax-L was approved, Americans who are uninsured (or underinsured) but diagnosed with GBM would fare better under Canada's healthcare system.
You know you don't have a leg to stand on when you're forced to deflect, discussing anything but the topic at hand.... and yes, I believe DCVax-L and Direct, which will be SOC treatments, with a combo car-t patent will result in an NWBO market cap of well over $100 billion ($100 pps). In fact, quadrupling these numbers, imho, would still be conservative.
Here's my original statement-- minus the deflection:
That's a pretty broad statement. Is it prudent to make that declaration without a patient population in mind (i.e., all patient populations would fare better under the U.S. healthcare system then Canada's)?
If DCVax-L is approved, the average Joe in Canada would likely get treatment because of universal coverage. The average Joe in the U.S who doesn't have insurance (albeit less of the population now due to OBAMAcare) will not get treatment. These people would fare better under Canada's system, for sure.
No matter the health system in place, DCVax-L would be a positive development for every country that accepts it... although some more than others, depending on access.
Great signature quote...
"Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world."
That's the norm these days. At least you feel sorry about it.
FWIW, I counted 49 excluding LL.
I was reading through an old 2015 NWBO PR and came across this:
damn, you're good bio...
Hear! Hear!
Phase II trials will complete in Sept 2023... Then they'll have to contend with a phase III, a minimum of 2/3 years if they are extremely lucky. Even if they are efficacious, by then DCVax-L and possibly Direct and other combinations would likely have moved the goal post.
I wish all of these companies success in moving us toward a cure to all cancers. I am confident DCVax-L, given the tld, and Direct will play the initial and key role to that end.
Thx.
I agree and can't wait for the journal article... let alone the approval application to be submitted and approved. I am grateful to be a small, inconsequential part of this effort.
According to your link, they have a phase I and two phase II trials. The phase II seems to be still enrolling.
It's a phase 1 trial.
Excellent points...
Definitely not. LP is asking for crazy money so Merck is looking for alternatives or ways to bring in more revenues. They know that if they want to survive, they'll have to deal with NWBO sooner or later.
I remember when cancer vaccines were not thought to be viable by BP. So now that the top two most knowledgeable, profitable and capable BPs are changing course, though belatedly, is very good news, imo. I don't think a phase2 melanoma trial will be a threat to DCVax-L given (1) the 12-year international trial data that will likely serve as a barrier of entry, (2) the trial is complete and the tld has been submitted to a journal and (3) manufacturing (and likely flaskwork automation & scalability) is nearing completion all before the melanoma p3 trial even starts.
Just saying... of course, I could be wrong.
... and that cancer vaccines are now worth pursuing.
Exactly....
Is this real or is it Merck's way of messaging NWBO to lower the BO price?
https://www.marketwatch.com/story/merck-moderna-to-develop-personalized-cancer-vaccine-01665575248?siteid=yhoof2
Wishful thinking... I doubt the SEC, DOJ will do anything. When NWBO's pps fell from $12 to 14 cents, did they do anything? AMC, GME and the buy-button halt? The entire financial market is about to collapse because of over-leverage with derivatives... again. Nothing was done back then, the 1st time, and nothing will be done now. NWBO, though bad, is small potatoes. I doubt it is even on DOJ/SEC's radar. I hope I am wrong...
No it was Bill Benny... but the video is still relavent.
I was listening to a YouTuber, Thomas James, discussing $100 Trillion dollars was stolen by Wallstreet via naked shorting. As evidence, he played a video of an ex-cia agent (GUESS WHO this agent might be?!?!?) discussing how the National security agencies have been tracking this for the last 15 years!!!
I am not sure, but if you compare the pics with google images, the agent looks like Cofer Black!!!!!
What do you think...
YouTube video:
Hear! Hear!